Nurix Receives $10M Payment as Sanofi Initiates Phase 1 Trial of STAT6 Degrader SAR448272
Nurix said Sanofi began a Phase 1 first-in-human trial of SAR448272/NX-3911, an oral STAT6 degrader, triggering a $10 million milestone payment. Nurix reported it has received about $139 million from its 2019 Sanofi collaboration and remains eligible for about $453 million in further STAT6-related milestones. Sanofi runs the trial, with U.S. co-development and co-promotion options for Nurix.
How this was made
The 30-second read
Why it matters
The disclosed $10M milestone and remaining $453M eligibility increase program-linked cash-flow visibility. The next decision point for Nurix is whether Phase 1 shows robust STAT6 degradation at tolerated doses, which could inform exercising its US co-development and co-promotion option.
Market read
Traders may treat this as a program milestone plus a near-term catalyst roadmap (Phase 1 dose-escalation target engagement), rather than a definitive efficacy signal.
What to watch
The article emphasizes target engagement/degradation depth, but does not provide dosing, safety signals, or early biomarker results, which are what typically drive repricing.
Background
Sanofi is running a Phase 1 first-in-human trial of SAR448272/NX-3911, an oral small-molecule degrader targeting STAT6, with Nurix receiving milestone cash under a 2019 collaboration.
Ticker impact
Nurix receives a $10M milestone from Sanofi after Phase 1 initiation of SAR448272/NX-3911, a STAT6 degrader tied to future $453M milestones.
Moderate positive bias for NRIX on trial-start/milestone headlines, with follow-through likely tied to Phase 1 dose-escalation target engagement readouts.
The article discloses a specific milestone payment ($10M) plus remaining eligibility ($453M) and links the next key catalyst to Phase 1 degradation/target engagement data, which can affect perceived probability of US co-promotion exercise.
Market effects
Highlights a shift toward oral small-molecule degraders in type 2 inflammation, potentially supporting sentiment for immunology degrader platforms.
Limited direct regional impact; US co-promotion option keeps US biotech investors engaged.
Sanofi-led trial execution can influence broader European pharma sentiment around STAT6 targeting and oral degrader modality.
Counterpoint
Milestone payments can be routine in collaborations, and Phase 1 success is not yet proof of efficacy versus existing biologics like dupilumab.
Key entities
- companyNurix
Receives a $10M milestone and retains eligibility for additional STAT6 program milestones; holds US co-development/co-promotion option.
- companySanofi
Initiates and conducts the Phase 1 trial of SAR448272/NX-3911 and is responsible for trial execution.
- drug_candidateSAR448272 / NX-3911
Oral small-molecule STAT6 degrader; Phase 1 first-in-human initiation is the trigger for the milestone payment.
- biological_targetSTAT6
Downstream effector in IL-4 and IL-13 signaling relevant to type 2 inflammation diseases.
